Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day c...
- Autores:
-
Tamma , Pranita
Villegas, María Virginia
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2017
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/3503
- Acceso en línea:
- http://hdl.handle.net/20.500.12495/3503
https://doi.org/10.1128/AAC.01094-17
https://repositorio.unbosque.edu.co
- Palabra clave:
- Beta-Lactamas
Inhibidores de beta-Lactamasas
Carbapenémicos
ESBLs
Bloodstream infection
Neutropenia
- Rights
- openAccess
- License
- Acceso abierto
| id |
UNBOSQUE2_d83158aabb4e2e6433abbfcd48468cce |
|---|---|
| oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/3503 |
| network_acronym_str |
UNBOSQUE2 |
| network_name_str |
Repositorio U. El Bosque |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| dc.title.translated.spa.fl_str_mv |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| title |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| spellingShingle |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population Beta-Lactamas Inhibidores de beta-Lactamasas Carbapenémicos ESBLs Bloodstream infection Neutropenia |
| title_short |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| title_full |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| title_fullStr |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| title_full_unstemmed |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| title_sort |
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population |
| dc.creator.fl_str_mv |
Tamma , Pranita Villegas, María Virginia |
| dc.contributor.author.none.fl_str_mv |
Tamma , Pranita Villegas, María Virginia |
| dc.contributor.orcid.none.fl_str_mv |
Villegas, María Virginia [0000-0003-1898-9067] |
| dc.subject.decs.spa.fl_str_mv |
Beta-Lactamas Inhibidores de beta-Lactamasas Carbapenémicos |
| topic |
Beta-Lactamas Inhibidores de beta-Lactamasas Carbapenémicos ESBLs Bloodstream infection Neutropenia |
| dc.subject.keywords.spa.fl_str_mv |
ESBLs Bloodstream infection Neutropenia |
| description |
β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients. |
| publishDate |
2017 |
| dc.date.issued.none.fl_str_mv |
2017 |
| dc.date.accessioned.none.fl_str_mv |
2020-07-15T20:51:25Z |
| dc.date.available.none.fl_str_mv |
2020-07-15T20:51:25Z |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.local.none.fl_str_mv |
Artículo de revista |
| dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
| format |
http://purl.org/coar/resource_type/c_6501 |
| dc.identifier.issn.none.fl_str_mv |
1098-6596 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/3503 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1128/AAC.01094-17 |
| dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
| dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
| dc.identifier.repourl.none.fl_str_mv |
https://repositorio.unbosque.edu.co |
| identifier_str_mv |
1098-6596 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque |
| url |
http://hdl.handle.net/20.500.12495/3503 https://doi.org/10.1128/AAC.01094-17 https://repositorio.unbosque.edu.co |
| dc.language.iso.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofseries.spa.fl_str_mv |
Antimicrobial agents and chemotherapy, 1098-6596, Vol. 61, Nro. 8, 2017 |
| dc.relation.uri.none.fl_str_mv |
https://aac.asm.org/content/61/8/e01094-17 |
| dc.rights.local.spa.fl_str_mv |
Acceso abierto |
| dc.rights.accessrights.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess Acceso abierto |
| dc.rights.creativecommons.none.fl_str_mv |
2017-06-05 |
| rights_invalid_str_mv |
Acceso abierto http://purl.org/coar/access_right/c_abf2 2017-06-05 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.none.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
American Society for Microbiology |
| dc.publisher.journal.spa.fl_str_mv |
Antimicrobial agents and chemotherapy |
| institution |
Universidad El Bosque |
| bitstream.url.fl_str_mv |
https://repositorio.unbosque.edu.co/bitstreams/23e0f743-cdf2-4169-9426-cdfc044d45d9/download https://repositorio.unbosque.edu.co/bitstreams/6c17f14c-8e1c-432a-814e-b079bb5bc94c/download https://repositorio.unbosque.edu.co/bitstreams/ff93ed98-e7bd-4513-95a8-25dfb52036d2/download https://repositorio.unbosque.edu.co/bitstreams/c0d006f9-f08d-4be9-a5fd-ddc12c432067/download |
| bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 1231b508ea755e848c3ee9e639e508ed 7210a811635d1799e7c05fee5d259be7 cd881e6079b9d1999f313c473de53626 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Universidad El Bosque |
| repository.mail.fl_str_mv |
bibliotecas@biteca.com |
| _version_ |
1808397486792900608 |
| spelling |
Tamma , PranitaVillegas, María VirginiaVillegas, María Virginia [0000-0003-1898-9067]2020-07-15T20:51:25Z2020-07-15T20:51:25Z20171098-6596http://hdl.handle.net/20.500.12495/3503https://doi.org/10.1128/AAC.01094-17instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquehttps://repositorio.unbosque.edu.coapplication/pdfengAmerican Society for MicrobiologyAntimicrobial agents and chemotherapyAntimicrobial agents and chemotherapy, 1098-6596, Vol. 61, Nro. 8, 2017https://aac.asm.org/content/61/8/e01094-17Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient populationUse of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient populationArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85Beta-LactamasInhibidores de beta-LactamasasCarbapenémicosESBLsBloodstream infectionNeutropeniaβ-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2017-06-05LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/23e0f743-cdf2-4169-9426-cdfc044d45d9/download8a4605be74aa9ea9d79846c1fba20a33MD52ORIGINALPranita D. Tamma, Maria Virginia Villegas_2020.pdfPranita D. Tamma, Maria Virginia Villegas_2020.pdfapplication/pdf145876https://repositorio.unbosque.edu.co/bitstreams/6c17f14c-8e1c-432a-814e-b079bb5bc94c/download1231b508ea755e848c3ee9e639e508edMD51THUMBNAILPranita D. Tamma, Maria Virginia Villegas_2020.pdf.jpgPranita D. Tamma, Maria Virginia Villegas_2020.pdf.jpgimage/jpeg5775https://repositorio.unbosque.edu.co/bitstreams/ff93ed98-e7bd-4513-95a8-25dfb52036d2/download7210a811635d1799e7c05fee5d259be7MD53TEXTPranita D. Tamma, Maria Virginia Villegas_2020.pdf.txtPranita D. Tamma, Maria Virginia Villegas_2020.pdf.txtExtracted texttext/plain15231https://repositorio.unbosque.edu.co/bitstreams/c0d006f9-f08d-4be9-a5fd-ddc12c432067/downloadcd881e6079b9d1999f313c473de53626MD5420.500.12495/3503oai:repositorio.unbosque.edu.co:20.500.12495/35032024-02-07 07:00:55.278restrictedhttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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 |